Patents by Inventor Nai-Kong V. Cheung

Nai-Kong V. Cheung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11987642
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 21, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Publication number: 20240026037
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., multi-specific antibodies or antigen binding fragments thereof) that can bind to the GPA33 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a GPA33-associated cancer in a subject in need thereof.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 25, 2024
    Inventors: Brian H. SANTICH, Mao WANG, Nai-Kong V. CHEUNG, Steven LARSON, Sarah CHEAL, Darren VEACH, Mahiuddin AHMED, Hong XU
  • Publication number: 20240002501
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.
    Type: Application
    Filed: March 6, 2023
    Publication date: January 4, 2024
    Inventors: Nai-Kong V. CHEUNG, Hong XU, Maya SUZUKI-NISHIJIMA, Brandon NEMIEBOKA, Jason LEWIS
  • Publication number: 20230374150
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g antibodies or antigen binding fragments thereof) that can bind to the PSMA protein. The antibodies of the present technology are useful in methods for detecting and treating a PSMA-associated pathology in a subject in need thereof.
    Type: Application
    Filed: October 11, 2021
    Publication date: November 23, 2023
    Inventors: Nai-Kong V. CHEUNG, Tsung-Yi LIN, Steven M. LARSON
  • Patent number: 11820832
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 21, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Publication number: 20230338493
    Abstract: The present disclosure relates generally to methods for determining whether a patient will show an enhanced immunogenic response to vaccines when using ?-glucan as a vaccine adjuvant.
    Type: Application
    Filed: June 9, 2021
    Publication date: October 26, 2023
    Inventors: Irene Y. Cheung, Nai-Kong V. Cheung
  • Publication number: 20230270857
    Abstract: The present disclosure provides ex vivo armed T cell (EAT) compositions that comprise multi-specific (e.g., bispecific) antibodies that bind to CDS and at least one additional target antigen (e.g., antigen that is expressed by tumor cells and/or a DOTA label). The EAT compositions of the present technology are useful for adoptive immunotherapy in a subject in need thereof.
    Type: Application
    Filed: July 27, 2021
    Publication date: August 31, 2023
    Inventors: Jeong A. Park, Nai-Kong V. Cheung, Brian Santich
  • Publication number: 20230235087
    Abstract: The present technology relates to the use of protein conjugates including a self-assembly and disassembly (SADA) polypeptide and a GD2-specific antigen binding domain for preventing or mitigating off-target tissue toxicity, such as brain, kidney, and/or myeloid damage, in a subject undergoing targeted alpha radioimmunotherapy. Also disclosed herein are pretargeted radioimmunotherapy (PRIT) methods that improve the durability of the anti-GD2-SADA conjugate anti-tumor response in vivo.
    Type: Application
    Filed: May 26, 2021
    Publication date: July 27, 2023
    Inventors: Brian H. Santich, Nai-Kong V. Cheung, Mahiuddin Ahmed
  • Publication number: 20230212289
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD3 protein. The antibodies of the present technology are useful in methods for detecting and treating cancer or a CD3 -associated pathology in a subject in need thereof.
    Type: Application
    Filed: April 23, 2021
    Publication date: July 6, 2023
    Inventors: Nai-Kong V. Cheung, Sayed Shahabuddin Hoseini, Hong Xu, Brian Santich, Mahiuddin Ahmed
  • Publication number: 20230158162
    Abstract: The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Inventors: Brian H. Santich, Mahiuddin Ahmed, Nai-Kong V. Cheung
  • Publication number: 20230095707
    Abstract: The present disclosure provides compositions and methods for the detection, and treatment of cancer. Specifically, the compositions of the present technology include multimodal fluorine-cyanine-DOTA-hapten compositions that may be complexed with a radioisotope (e.g., 175Lu). Also disclosed herein are methods of using the fluorine-cyanine-DOTA-hapten compositions of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: December 30, 2020
    Publication date: March 30, 2023
    Inventors: Nai-Kong V. CHEUNG, Steven M. LARSON, Sarah CHEAL, Richard TING, Hari Krishna KOMMIDI, Feifei AN, Brian SANTICH
  • Patent number: 11597764
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 7, 2023
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong V. Cheung, Hong Xu, Maya Suzuki-Nishijima, Brandon Nemieboka, Jason Lewis
  • Patent number: 11583588
    Abstract: The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 21, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Brian H. Santich, Mahiuddin Ahmed, Nai-Kong V. Cheung
  • Patent number: 11529371
    Abstract: Provided are anti-CD33 antibody agents, including anti-CD33 antibody agents in an IgG-scFv format. Various methods and reagents related thereto are also provided, including for example for the detection, prevention, and/or therapeutical treatment of CD33-related diseases, in particular, leukemias such as AML.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: December 20, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Sayed Shahabuddin Hoseini, Nai-Kong V. Cheung
  • Publication number: 20220348686
    Abstract: The present technology relates generally to the preparation of immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that specifically bind STEAP1 protein and uses of the same. In particular, the present technology relates to the preparation of STEAP1 binding antibodies and their use in detecting and treating STEAP1-associated cancers.
    Type: Application
    Filed: September 4, 2020
    Publication date: November 3, 2022
    Inventors: Nai-Kong V. CHEUNG, Tsung-Yi LIN, Steven M. LARSON
  • Publication number: 20220259307
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CDS 3-associated cancer in a subject in need thereof.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 18, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong V. CHEUNG, Sayed Shahabuddin HOSEINI, Mahiuddin AHMED
  • Publication number: 20220251192
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CD33-associated cancer in a subject in need thereof.
    Type: Application
    Filed: June 25, 2020
    Publication date: August 11, 2022
    Inventors: Nai-Kong V. Cheung, Sayed Shahabuddin Hoseini
  • Publication number: 20220177579
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD 19 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD 19- associated autoimmune disease or a CD19-associated cancer in a subject in need thereof.
    Type: Application
    Filed: April 7, 2020
    Publication date: June 9, 2022
    Inventors: Nai-Kong V. CHEUNG, Sayed Shahabuddin HOSEINI, Mahiuddin AHMED
  • Publication number: 20220177581
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD22 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD22-associated cancer, a CD22-associated autoimmune disease, or a CD22-associated allergy in a subject in need thereof.
    Type: Application
    Filed: March 10, 2020
    Publication date: June 9, 2022
    Inventors: Nai-Kong V. CHEUNG, Sayed Shahabuddin HOSEINI, Mahiuddin AHMED
  • Publication number: 20220106375
    Abstract: The present disclosure relates generally to complexes comprising an interleukin-15 (“EL-15”) polypeptide chain non-covalently bonded to an IL-15 receptor ?-Fc fusion polypeptide (“IL-15R?-Fc”), and multimers (e.g., trimers) thereof. The complexes of the present technology are useful in methods for enhancing immune cell function and immunotherapy in a patient in need thereof. Also provided herein are methods for preventing or treating a disease or condition in which enhancing IL-15-mediated function is beneficial (such as cancer, infectious diseases, immunodeficiencies and leukopenia) in a patient in need thereof.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 7, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. CHEUNG, Hong XU